Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
NCT01057888 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10599
Last updated 2016-01-20
Summary
The investigators will design and implement a randomized clinical trial to test, on a community-wide level, the effectiveness of managed care based tracking/reminder/recall on improving vaccination coverage among adolescents.
The investigators propose a randomized controlled trial to evaluate the effectiveness of reminder/recall for adolescents: 10,599 adolescents within the managed care organization (MCO) will be randomized into one of three arms: 1) mailed reminders, 2) autodialer telephone messages or 3) standard of care of their practice (no messages from the intervention).
Hypothesis 1: Reminder/recall will increase the receipt of immunizations and preventive services
Hypothesis 2: Telephone (autodialer) reminders will be more effective than mailed reminders
Hypothesis 3: The impact of reminders will be greatest for the most high-risk subgroups which have low baseline immunization rates.
Hypothesis 4: Mailed reminders will be more costly (and less effective) than telephone reminders.
Conditions
- Immunization Status
- Well Child Care Visit
Interventions
- OTHER
-
Autodialer
Autodialer telephone calls
- OTHER
-
Letters
Mailed reminder letters
Sponsors & Collaborators
-
Centers for Disease Control and Prevention
collaborator FED -
University of California, Los Angeles
lead OTHER
Principal Investigators
-
Peter G Szilagyi, MD, MPH · University of Rochester
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 11 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-12-31
- Primary Completion
- 2010-12-31
- Completion
- 2010-12-31
More Related Trials
-
Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions
NCT02231957 ·Status: COMPLETED ·Phase: NA
-
Adolescent Vaccination Kiosk Project
NCT01622608 ·Status: COMPLETED ·Phase: NA
-
The Efficacy of Reminders to Complete HPV Series
NCT01731496 ·Status: COMPLETED ·Phase: NA
-
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose
NCT01439165 ·Status: COMPLETED ·Phase: PHASE4
-
A School Health Center Intervention to Increase Adolescent Vaccination
NCT01595542 ·Status: COMPLETED ·Phase: NA
-
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine
NCT00304265 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
NCT00457249 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
NCT07203755 ·Status: RECRUITING ·Phase: PHASE1
-
Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose
NCT00712959 ·Status: COMPLETED ·Phase: PHASE4
-
Development and Testing of ADEPT: A Parent Decision Support for Childhood Vaccinations
NCT04496453 ·Status: COMPLETED ·Phase: NA
-
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
NCT00347958 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
NCT01629589 ·Status: COMPLETED ·Phase: PHASE4
-
Parental Views Related to Colorado State Legislation About Vaccinations, Schools, and Child Care Centers
NCT02957344 ·Status: COMPLETED
-
Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers
NCT05993325 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age
NCT00524732 ·Status: COMPLETED
-
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
NCT00258882 ·Status: COMPLETED
-
Understanding Typhoid Disease After Vaccination
NCT01405521 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine
NCT00777257 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea
NCT01642589 ·Status: COMPLETED ·Phase: PHASE3
-
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
NCT00109330 ·Status: COMPLETED ·Phase: PHASE3
-
4 Pillars Toolkit for Adolescent Vaccination
NCT02165722 ·Status: COMPLETED ·Phase: NA
-
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
NCT00355121 ·Status: COMPLETED ·Phase: PHASE2
-
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)
NCT00325130 ·Status: COMPLETED ·Phase: PHASE3
-
School Located Adolescent Vaccination Study
NCT01719679 ·Status: COMPLETED ·Phase: NA
-
The 3rd COPENHAGEN Puberty Study
NCT04884620 ·Status: RECRUITING